Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413129430> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W2413129430 endingPage "52" @default.
- W2413129430 startingPage "49" @default.
- W2413129430 abstract "The search for new combination chemotherapeutic regimens for the treatment of non-small-cell lung cancer is motivated not only by the desire to increase the objective tumor response and survival rates, but also by the desire to reduce toxicity, decrease symptoms, and improve the psychological well-being of treated patients. At present, the overall phase II response rates with existing combination chemotherapeutic regimens are approximately 15% to 30%, and the median survival rates are about 8 to 9 months. The median 1-year survival rates are about 30% to 40%, while the 2-year survival rates are only about 10% to 15%. Thus, while we have made substantial progress in the treatment of this disease, the long-term outcome is still relatively bleak. This article reviews the results of a phase I trial with a new combination chemotherapeutic regimen (gemcitabine [Gemzar] and the novel antifolate, Alimta), and outlines the rationale for, and design of, an ongoing phase II trial." @default.
- W2413129430 created "2016-06-24" @default.
- W2413129430 creator A5019357584 @default.
- W2413129430 date "2000-07-01" @default.
- W2413129430 modified "2023-09-25" @default.
- W2413129430 title "Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer." @default.
- W2413129430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10981291" @default.
- W2413129430 hasPublicationYear "2000" @default.
- W2413129430 type Work @default.
- W2413129430 sameAs 2413129430 @default.
- W2413129430 citedByCount "5" @default.
- W2413129430 crossrefType "journal-article" @default.
- W2413129430 hasAuthorship W2413129430A5019357584 @default.
- W2413129430 hasConcept C126322002 @default.
- W2413129430 hasConcept C143998085 @default.
- W2413129430 hasConcept C2776256026 @default.
- W2413129430 hasConcept C2776694085 @default.
- W2413129430 hasConcept C2780258809 @default.
- W2413129430 hasConcept C2781413609 @default.
- W2413129430 hasConcept C71924100 @default.
- W2413129430 hasConceptScore W2413129430C126322002 @default.
- W2413129430 hasConceptScore W2413129430C143998085 @default.
- W2413129430 hasConceptScore W2413129430C2776256026 @default.
- W2413129430 hasConceptScore W2413129430C2776694085 @default.
- W2413129430 hasConceptScore W2413129430C2780258809 @default.
- W2413129430 hasConceptScore W2413129430C2781413609 @default.
- W2413129430 hasConceptScore W2413129430C71924100 @default.
- W2413129430 hasIssue "7 Suppl 4" @default.
- W2413129430 hasLocation W24131294301 @default.
- W2413129430 hasOpenAccess W2413129430 @default.
- W2413129430 hasPrimaryLocation W24131294301 @default.
- W2413129430 hasRelatedWork W1587223989 @default.
- W2413129430 hasRelatedWork W2056002207 @default.
- W2413129430 hasRelatedWork W2058040425 @default.
- W2413129430 hasRelatedWork W2073104701 @default.
- W2413129430 hasRelatedWork W2166944779 @default.
- W2413129430 hasRelatedWork W2383259583 @default.
- W2413129430 hasRelatedWork W2439707001 @default.
- W2413129430 hasRelatedWork W2468005262 @default.
- W2413129430 hasRelatedWork W81274823 @default.
- W2413129430 hasRelatedWork W2184311402 @default.
- W2413129430 hasVolume "14" @default.
- W2413129430 isParatext "false" @default.
- W2413129430 isRetracted "false" @default.
- W2413129430 magId "2413129430" @default.
- W2413129430 workType "article" @default.